



**Biocon Limited**  
20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

Date of submission: December 19, 2018

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

**Sub: Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU**  
**Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the “Company Statement” on the subject matter.

*“Ogivri®, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, has been approved in the EU. The European Commission has granted Marketing Authorization for Ogivri to our partner Mylan.*

*The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) previously issued a positive opinion recommending approval of Ogivri as a biosimilar to Roche’s Herceptin® (Trastuzumab) on October 18, 2018.*

*Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC). Under supervision of the relevant healthcare professional it can be prescribed as either monotherapy or in combination with other medicines dependent on the relevant diagnosis.” – Company Spokesperson*

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,  
Yours faithfully  
For Biocon Limited

Satish Kumar S S  
Company Secretary & Compliance Officer